Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Abstract Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematologic...

Full description

Bibliographic Details
Main Authors: C. Grandclément, C. Estoppey, E. Dheilly, M. Panagopoulou, T. Monney, C. Dreyfus, J. Loyau, V. Labanca, A. Drake, S. De Angelis, A. Rubod, J. Frei, L. N. Caro, S. Blein, E. Martini, M. Chimen, T. Matthes, Z. Kaya, C. M. Edwards, J. R. Edwards, E. Menoret, C. Kervoelen, C. Pellat-Deceunynck, P. Moreau, M. L. Mbow, A. Srivastava, M. R. Dyson, E. A. Zhukovsky, M. Perro, S. Sammicheli
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-46310-y

Internet

https://doi.org/10.1038/s41467-024-46310-y

Similar Items